cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy

Morgan L. Cowan, Christopher VandenBussche

Research output: Contribution to journalReview article

Abstract

Initial evaluation of patients presenting with a suspected malignancy without a clear clinical or radiologic impression of a primary site (so-called cancer of unknown primary, or CUP) frequently includes fine needle aspiration (FNA) to both establish a diagnosis and procure tissue for additional studies. Careful management of limited specimen material is especially important in the modern era, when molecular studies may take precedence over a more definitive tissue diagnosis. This review summarizes our practice habits when encountering a CUP. Broadly, key morphologic patterns in context of patient history and clinical-radiologic impression should guide the selection of a limited panel of IPOX stains to establish first a broad lineage. Subsequently 1–2 site-specific markers may be used to confirm the diagnosis. In difficult cases, it is helpful to convey the situation to the treating physicians, who may prefer to prioritize molecular testing over pursuit of a more definitive diagnosis. Prudent choice of immunoperoxidase (IPOX) studies, based on both key cytomorphologic criteria and continued communications with the clinical team regarding their needs for treatment planning, is critical in CUP cases.

Original languageEnglish (US)
Pages (from-to)724-737
Number of pages14
JournalCancer cytopathology
Volume126
DOIs
StatePublished - Aug 1 2018

Fingerprint

Biopsy
Neoplasms
Therapeutics
Fine Needle Biopsy
Habits
Coloring Agents
Communication
Physicians

Keywords

  • cancer of unknown primary
  • carcinoma of unknown primary
  • fine needle aspiration
  • unknown origin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

cancer of unknown primary : Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy. / Cowan, Morgan L.; VandenBussche, Christopher.

In: Cancer cytopathology, Vol. 126, 01.08.2018, p. 724-737.

Research output: Contribution to journalReview article

@article{db0db1cb077a4be6bc354466d5be61d0,
title = "cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy",
abstract = "Initial evaluation of patients presenting with a suspected malignancy without a clear clinical or radiologic impression of a primary site (so-called cancer of unknown primary, or CUP) frequently includes fine needle aspiration (FNA) to both establish a diagnosis and procure tissue for additional studies. Careful management of limited specimen material is especially important in the modern era, when molecular studies may take precedence over a more definitive tissue diagnosis. This review summarizes our practice habits when encountering a CUP. Broadly, key morphologic patterns in context of patient history and clinical-radiologic impression should guide the selection of a limited panel of IPOX stains to establish first a broad lineage. Subsequently 1–2 site-specific markers may be used to confirm the diagnosis. In difficult cases, it is helpful to convey the situation to the treating physicians, who may prefer to prioritize molecular testing over pursuit of a more definitive diagnosis. Prudent choice of immunoperoxidase (IPOX) studies, based on both key cytomorphologic criteria and continued communications with the clinical team regarding their needs for treatment planning, is critical in CUP cases.",
keywords = "cancer of unknown primary, carcinoma of unknown primary, fine needle aspiration, unknown origin",
author = "Cowan, {Morgan L.} and Christopher VandenBussche",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/cncy.22014",
language = "English (US)",
volume = "126",
pages = "724--737",
journal = "Cancer cytopathology",
issn = "1934-662X",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - cancer of unknown primary

T2 - Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy

AU - Cowan, Morgan L.

AU - VandenBussche, Christopher

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Initial evaluation of patients presenting with a suspected malignancy without a clear clinical or radiologic impression of a primary site (so-called cancer of unknown primary, or CUP) frequently includes fine needle aspiration (FNA) to both establish a diagnosis and procure tissue for additional studies. Careful management of limited specimen material is especially important in the modern era, when molecular studies may take precedence over a more definitive tissue diagnosis. This review summarizes our practice habits when encountering a CUP. Broadly, key morphologic patterns in context of patient history and clinical-radiologic impression should guide the selection of a limited panel of IPOX stains to establish first a broad lineage. Subsequently 1–2 site-specific markers may be used to confirm the diagnosis. In difficult cases, it is helpful to convey the situation to the treating physicians, who may prefer to prioritize molecular testing over pursuit of a more definitive diagnosis. Prudent choice of immunoperoxidase (IPOX) studies, based on both key cytomorphologic criteria and continued communications with the clinical team regarding their needs for treatment planning, is critical in CUP cases.

AB - Initial evaluation of patients presenting with a suspected malignancy without a clear clinical or radiologic impression of a primary site (so-called cancer of unknown primary, or CUP) frequently includes fine needle aspiration (FNA) to both establish a diagnosis and procure tissue for additional studies. Careful management of limited specimen material is especially important in the modern era, when molecular studies may take precedence over a more definitive tissue diagnosis. This review summarizes our practice habits when encountering a CUP. Broadly, key morphologic patterns in context of patient history and clinical-radiologic impression should guide the selection of a limited panel of IPOX stains to establish first a broad lineage. Subsequently 1–2 site-specific markers may be used to confirm the diagnosis. In difficult cases, it is helpful to convey the situation to the treating physicians, who may prefer to prioritize molecular testing over pursuit of a more definitive diagnosis. Prudent choice of immunoperoxidase (IPOX) studies, based on both key cytomorphologic criteria and continued communications with the clinical team regarding their needs for treatment planning, is critical in CUP cases.

KW - cancer of unknown primary

KW - carcinoma of unknown primary

KW - fine needle aspiration

KW - unknown origin

UR - http://www.scopus.com/inward/record.url?scp=85052531969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052531969&partnerID=8YFLogxK

U2 - 10.1002/cncy.22014

DO - 10.1002/cncy.22014

M3 - Review article

C2 - 30156769

AN - SCOPUS:85052531969

VL - 126

SP - 724

EP - 737

JO - Cancer cytopathology

JF - Cancer cytopathology

SN - 1934-662X

ER -